본문 바로가기

Current Status of Supersaturable Self-Emulsifying Drug Delivery Systems

문서 유형
연구출판물 · 리뷰논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q2
저널
PHARMACEUTICS12(4) · 2020
피인용
Web of Science 79Scopus 108
FWCI (Scopus)
0
JCR IF
JCR 2019 4.421
ISSN
1999-4923

저자

  1. 박희준제1저자College of Pharmacy, Pusan National University, 63 Busandaehak-ro, Geumjeong-gu, Busan, 46241, Korea
  2. 하은솔College of Pharmacy, Pusan National University, 63 Busandaehak-ro, Geumjeong-gu, Busan, 46241, Korea
  3. 김민수교신저자College of Pharmacy, Pusan National University, 63 Busandaehak-ro, Geumjeong-gu, Busan, 46241, Korea

초록

Self-emulsifying drug delivery systems (SEDDSs) are a vital strategy to enhance the bioavailability (BA) of formulations of poorly water-soluble compounds. However, these formulations have certain limitations, including in vivo drug precipitation, poor in vitro in vivo correlation due to a lack of predictive in vitro tests, issues in handling of liquid formulation, and physico-chemical instability of drug and/or vehicle components. To overcome these limitations, which restrict the potential usage of such systems, the supersaturable SEDDSs (su-SEDDSs) have gained attention based on the fact that the inclusion of precipitation inhibitors (PIs) within SEDDSs helps maintain drug supersaturation after dispersion and digestion in the gastrointestinal tract. This improves the BA of drugs and reduces the variability of exposure. In addition, the formulation of solid su-SEDDSs has helped to overcome disadvantages of liquid or capsule dosage form. This review article discusses, in detail, the current status of su-SEDDSs that overcome the limitations of conventional SEDDSs. It discusses the definition and range of su-SEDDSs, the principle mechanisms underlying precipitation inhibition and enhanced in vivo absorption, drug application cases, biorelevance in vitro digestion models, and the development of liquid su-SEDDSs to solid dosage forms. This review also describes the effects of various physiological factors and the potential interactions between PIs and lipid, lipase or lipid digested products on the in vivo performance of su-SEDDSs. In particular, several considerations relating to the properties of PIs are discussed from various perspectives.

키워드

su-SEDDSsupersaturationprecipitation inhibitor (PI)in vitro digestion modelsolid dosage formstabilityphysiological factorsbioavailabilityLIPID-BASED FORMULATIONSIN-VITRO TESTSWATER-SOLUBLE DRUGSENHANCED ORAL BIOAVAILABILITYLIPASE-MEDIATED DIGESTIONVIVO BIOAVAILABILITYPRECIPITATION INHIBITORSGASTROINTESTINAL-TRACTCOMPUTATIONAL MODELSCONTROLLED-RELEASE

식별자

Scopus EID
2-s2.0-85084491353
WoS UID
000535575000070